Vaderis Therapeutics closed an oversubscribed $152 million Series B to advance engasertib into Phase 3 for hereditary hemorrhagic telangiectasia (HHT). The financing coincided with the initiation of the global HEROIC Phase 3 study (NCT07743671). Engasertib—previously known as ALM 301—targets HHT biology through an oral allosteric AKT inhibitor mechanism. Vaderis said there are currently no approved therapies for HHT anywhere globally, underscoring the unmet need tied to severe nosebleeds, anemia, and arteriovenous malformations. The round was co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital and existing investors Medicxi and Droia. Vaderis said the capital is intended to carry operations through potential U.S. regulatory approval. For the biotech sector, the deal stands out as continued appetite for late-stage rare disease programs that convert scientific rationale into an executable Phase 3 roadmap.